The US Food and Drug Administration approved CSPC Pharmaceutical's (HKG:1093) clinical trials for its SYH2051 for advanced solid tumors, according to a Thursday filing with the Hong Kong exchange.
The drug is an ataxia telangiectasia mutated or ATM inhibitor, which delays the repair of DNA double-strand breaks in tumor cells, the filing said.
SYH2051 showed good selectivity of ATM targets, according to the filing.
The drug also obtained China approval for clinical trials in June 2023.
Shares rose 2% during Friday's afternoon trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。